Lilly’s Omvoh is an IL23p19-targeting monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Image credit: Tada Images / Shutterstock.

Eli Lilly has released histological data from the Phase III VIVID-1 trial showing that its Crohn’s disease therapy Omvoh (mirikizumab) was superior to Johnson & Johnson’s (J&J) Stelara (ustekinumab).

Whilst Omvoh is not yet approved by the US Food and Drug Administration (FDA) to treat Crohn’s disease, it was approved for ulcerative colitis (UC), another type of inflammatory bowel disease (IBD). Lilly’s therapy is facing stiff competition in the IBD market from established high-grossing drugs such as AbbVie’s Humira (adalimumab) and J&J’s Stelara (ustekinumab).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Humira and Stelara generated $6.9bn and $10.8bn in global sales last year, respectively. Humira has already seen a decline in its profits with the introduction of biosimilars, with AbbVie reporting a 31.9% decline in the therapy’s revenue due to biosimilar competition in 2023 compared to the previous year. J&J has also made moves to position another of its monoclonal antibodies, Tremfya (guselkumab), as a successor to Stelara, which has already found success in the IBD space.

GlobalData forecasts Omvoh sales to trail behind Tremfya, with the therapies expected to generate $1.2bn and $7.7bn in global sales in 2029, respectively.

GlobalData is the parent company of Clinical Trials Arena.

The Phase III VIVID-1 trial (NCT03926130) pitted Omvoh against Stelara and placebo over one year. Lilly noted that Omvoh achieved “nominally statistically significant” improvements across all histologic and histologic-endoscopic endpoints compared to Stelara and placebo. At 52 weeks, 58.2% of patients achieved histologic response with Omvoh, compared to 48.8% of patients in the Stelara group, regardless of biologic treatment history. Similar results were observed in patients who had active histologic disease at baseline and with at least one prior biologic treatment failure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

At 52 weeks, 39.6% of patients had endoscopic-histologic response with Omvoh, compared to 27.8% in the Stelara group. The frequency of serious adverse events was greater in the placebo group compared to Omvoh. Commonly observed side effects included Covid-19, anaemia, arthralgia, headache, upper respiratory tract infection, nasopharyngitis and injection site reactions.

Lilly has filed for approval of Omvoh in Crohn’s disease with multiple global regulatory health authorities, including the FDA. The company is also evaluating the therapy for IBD in paediatric patients in three Phase III trials (NCT04844606, NCT05509777 and NCT05784246).